Baxter International Inc. (NYSE:BAX) Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC increased its stake in Baxter International Inc. (NYSE:BAX - Free Report) by 21.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,438 shares of the medical instruments supplier's stock after purchasing an additional 8,393 shares during the period. TD Private Client Wealth LLC's holdings in Baxter International were worth $1,624,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Amundi lifted its stake in Baxter International by 41.1% in the fourth quarter. Amundi now owns 1,319,274 shares of the medical instruments supplier's stock worth $39,037,000 after acquiring an additional 384,349 shares during the period. EverSource Wealth Advisors LLC lifted its position in Baxter International by 93.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 6,455 shares of the medical instruments supplier's stock valued at $188,000 after buying an additional 3,123 shares during the period. Farther Finance Advisors LLC raised its position in shares of Baxter International by 61.2% in the 4th quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier's stock worth $118,000 after purchasing an additional 1,541 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its position in shares of Baxter International by 35.1% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 2,548,215 shares of the medical instruments supplier's stock worth $74,306,000 after purchasing an additional 662,042 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Baxter International by 5.8% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 13,618 shares of the medical instruments supplier's stock worth $397,000 after purchasing an additional 752 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Morgan Stanley cut their price target on Baxter International from $30.00 to $28.00 and set an "underweight" rating for the company in a research note on Monday, May 5th. Wells Fargo & Company lowered their price target on Baxter International from $36.00 to $33.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Wall Street Zen raised Baxter International from a "hold" rating to a "buy" rating in a report on Sunday, June 22nd. Citigroup decreased their price objective on Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a report on Wednesday. Finally, Evercore ISI cut their target price on Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.50.

Baxter International Stock Down 2.6%

Shares of NYSE BAX traded down $0.80 during mid-day trading on Wednesday, reaching $29.86. 7,164,020 shares of the company were exchanged, compared to its average volume of 4,347,968. The company has a quick ratio of 1.40, a current ratio of 2.02 and a debt-to-equity ratio of 1.33. The stock has a market cap of $15.32 billion, a price-to-earnings ratio of -27.15, a P/E/G ratio of 0.87 and a beta of 0.61. Baxter International Inc. has a 1 year low of $26.25 and a 1 year high of $40.49. The firm has a 50-day moving average of $30.64 and a 200 day moving average of $31.25.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.14. Baxter International had a positive return on equity of 17.24% and a negative net margin of 4.71%. The company had revenue of $2.63 billion during the quarter, compared to analysts' expectations of $2.59 billion. During the same period last year, the business posted $0.65 earnings per share. The firm's revenue was up 5.4% compared to the same quarter last year. On average, research analysts expect that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Friday, May 30th were paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date was Friday, May 30th. Baxter International's dividend payout ratio (DPR) is presently -61.82%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.